Every 10-Q that Invivyd, Inc. (IVVD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IVVD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVVD filings page.
Invivyd, Inc. reports that for the six months ended June 30, 2026 it generated $28.0 million in net product revenue, up from $23.1 million a year earlier, driven by sales of PEMGARDA. However, total operating costs and expenses rose to $117.0 million, leading to a net loss of $85.8 million versus $30.9 million in the prior-year period.
Cash and cash equivalents were $160.1 million at June 30, 2026, down from $226.7 million at December 31, 2025, after $84.7 million of net cash used in operating activities in the first half. Stockholders’ equity declined to $181.1 million from $241.5 million, and the accumulated deficit reached $1,040.3 million. Management states there is substantial doubt about the company’s ability to continue as a going concern because existing cash is not expected to fund operations beyond one year without additional financing.
PEMGARDA holds U.S. FDA emergency use authorization for pre-exposure prophylaxis of COVID-19, but the EUA is set to terminate on June 29, 2027 following a declared transition period. Invivyd is advancing VYD2311, a next-generation COVID-19 monoclonal antibody, through Phase 3 clinical trials (DECLARATION and LIBERTY) with top-line data planned later in the third quarter of 2026, and is progressing RSV and measles antibody candidates toward IND readiness.
Invivyd, Inc. reported higher product revenue but significantly larger losses for the quarter ended March 31, 2026. Revenue rose to $13.7 million from $11.3 million, driven by sales of its COVID-19 antibody PEMGARDA. Operating costs climbed sharply, with research and development at $30.7 million and selling, general and administrative at $25.1 million, leading to a net loss of $41.4 million, up from $16.3 million a year earlier.
Cash and cash equivalents fell to $184.2 million from $226.7 million at year-end, with operating cash outflows of $41.7 million in the quarter and an accumulated deficit of $995.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond one year without additional financing. Invivyd continues advancing its pipeline, including Phase 3 trials for COVID-19 antibody VYD2311 and preclinical RSV and measles programs, while also maintaining access to an undrawn senior loan facility and an at-the-market equity program.
Invivyd, Inc. reported Q3 2025 results showing higher revenue and sharply lower operating expenses, alongside a going concern warning. Product revenue reached $13.1 million, up from $9.3 million a year ago. The net loss narrowed to $10.5 million from $60.7 million, driven by a large decline in research and development expense ($8.0 million vs. $57.9 million). Cash and cash equivalents were $84.97 million, up from $69.35 million at year-end.
The company strengthened liquidity through equity financings, including an underwritten public offering and at‑the‑market sales, bringing in $58.45 million of net cash in the nine months ended September 30, 2025. Stockholders’ equity improved to $93.07 million from $67.54 million. Management disclosed “substantial doubt” about the ability to continue as a going concern without additional funding.
Operationally, PEMGARDA remains authorized under EUA. The FDA cleared the IND for VYD2311 in October 2025, with Phase 3 trials (DECLARATION and LIBERTY) expected to begin around year‑end 2025 and top‑line data anticipated mid‑2026. As of October 30, 2025, shares outstanding were 233,122,834.
Invivyd, Inc. reported operational and financing disclosures in its Form 10-Q, including capital structure, third-party agreements and program cost changes. The company noted Emergency Use Authorization for PEMGARDA in March 2024 and that sales of PEMGARDA have funded operations. During the period the company sold 9,000,000 shares under an at-the-market facility for net proceeds of $39.3 million at an average price of $4.50 per share and had $325 million of securities remaining on its shelf registration as of June 30, 2025. A $30 million Term Facility is available in three tranches subject to financial covenants and net product revenue milestones; as of June 30, 2025 the company had not met the revenue milestone required to draw on the earliest tranche. Material contractual items include significant Adimab obligations (quarterly fees of $0.6 million and royalty terms, including 45%–55% on certain compulsory sublicenses), lease liabilities of $1.1 million (current) and $1.9 million (non-current), and stock plans and equity awards including 1,700,000 RSUs granted at $1.61 per share.